Oncolytics Logo
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

News Releases

  • News Releases
Latest News Release
Dec 27, 2017

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas

Dec 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer

Dec 4, 2017

Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit

Nov 30, 2017

Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer

Nov 16, 2017

Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

Nov 8, 2017

Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results

Nov 2, 2017

Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

Oct 11, 2017

Oncolytics Biotech® to Present at the 2017 BIO Investor Forum

  • 1
  • 2
  • 3
  • 4
  • 5

Year
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • News
Dec 27, 2017

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Dec 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles
Aug 9, 2016

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

@Oncolytics Apr 8, 2021

CEO Matt Coffey will participate in the Off-the-Shelf CAR T - solid tumors, myeloma, lymphoma panel at Canaccord’s… https://t.co/DlQMsCYZRD

@Oncolytics Apr 7, 2021

RT @LifeSciAdvisors: Join us for the @Oncolytics KOL Webinar on AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer…

Follow us on Twitter
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

Sign up to receive email updates

Sign Up
Linkedin Icon
  • Privacy | Legal Notice
Copyright © Oncolytics Biotech® Inc. 2021 All rights reserved

Site by
Site by Pace Creative Alberta Site by Pace Creative Alberta